National Alliance on Mental Illness

RESEARCH OPPORTUNITY

NAMI is committed to improving the lives of people impacted by mental health conditions through effective treatments, equitable public policies, and greater knowledge and understanding in society. Research is essential to advance each of these goals. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting research participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these studies.

If you have questions about research at NAMI, please visit NAMI.org/research or email research@nami.org.

WHAT IS THE STUDY?

This study is a phase 2 clinical trial to test the safety and efficacy of different doses of the oral medication, BI 1569912, as an adjunct, or supplemental, treatment for individuals with major depressive disorder (MDD) who are already taking an antidepressant but are still experiencing symptoms. Participants will be randomly assigned to receive 1 of 4 doses of the trial drug or a placebo. Participation will last up to 11 weeks, including 6 weeks of taking the trial drug or placebo once every day and visiting a trial center up to 7 times for health screenings. Participants will continue their current medication and/or other therapy throughout the study. Participants may be reimbursed for trial-related costs, such as travel to and from the trial site, or hotel stays. Reimbursements cover necessary travel expenses like meals, mileage, tolls, parking and incidentals. For more information on reimbursement and compensation, participants should contact their trial site.

WHO CAN PARTICIPATE?

Participants may be eligible for this study if they:

- Are between the ages of 18 and 65
- Have been diagnosed with major depressive disorder (MDD)
- Are already taking antidepressants, but find they are not working well enough to reduce symptoms

The researchers are seeking 204 people for this study.

WHERE IS THE STUDY TAKING PLACE?

This is a global, multicenter study with sites located in the following states: Arizona, Connecticut, Florida, Massachusetts, New Jersey, New York, Oklahoma, and Texas.

HOW DO I LEARN MORE?

The study flyer has additional information about the study. If you have questions or would like more information, including specific site locations, please contact Boehringer Ingelheim at 1-800-243-0127 or clintriage.rdg@boehringer-ingelheim.com or visit https://classic.clinicaltrials.gov/ct2/show/NCT06280235.